Want to see CMPX full AI Analyst Report?
CMPX Stock Chart & Stats
$2.07
$0.10(4.59%)
At close: 4:00 PM EDT
$2.07
$0.10(4.59%)
Day’s Range― - ―
52-Week Range$1.61 - $6.88
Previous CloseN/A
Volume336.06K
Average Volume (3M)2.82M
Market Cap
$416.00M
Enterprise Value$238.84
Total Cash (Recent Filing)$179.88M
Total Debt (Recent Filing)$9.63M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding180,087,920
10 Day Avg. Volume1,863,301
30 Day Avg. Volume2,817,627
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.33Price Target Upside350.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial Equity BaseLow debt relative to equity and a sizable asset base provide financial flexibility for ongoing development. This reduces near-term balance-sheet pressure, although continued losses could gradually weaken the capital base.
Promising Late-stage Clinical DataPositive Phase 2/3 data in biliary tract cancer strengthens the lead asset’s clinical and commercial potential. If confirmed and accepted by regulators, the result could support differentiation, partnership interest, and eventual product revenue.
Defined Development Plan And Diversified Oncology PipelineA defined regulatory path, multiple clinical milestones, and additional oncology programs create several potential value inflection points. The stated runway also supports continued execution while the company advances its lead candidate toward commercialization.
Bears Say
Minimal Revenue And Widening LossesThe company has not demonstrated meaningful commercial traction, leaving clinical development as the primary source of potential value. Persistent and widening losses increase execution risk and make future success dependent on pipeline progress.
Heavy Ongoing Cash BurnSustained negative operating and free cash flow shows that the business cannot currently fund operations internally. Continued investment in trials and commercialization preparation may require external financing, creating dilution or funding risk.
Capital Base Is Vulnerable To Continued LossesAlthough leverage is low, ongoing losses are eroding shareholder capital and reducing the durability of the balance-sheet cushion. If cash burn persists or trials require greater spending, financial flexibility could narrow before products generate revenue.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics, Inc.’s price range in the past 12 months?
Compass Therapeutics, Inc. lowest stock price was $1.61 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics, Inc.’s market cap?
Compass Therapeutics, Inc.’s market cap is $416.00M.
When is Compass Therapeutics, Inc.’s upcoming earnings report date?
Compass Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 84 days.
How were Compass Therapeutics, Inc.’s earnings last quarter?
Compass Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.019.
Is Compass Therapeutics, Inc. overvalued?
According to Wall Street analysts Compass Therapeutics, Inc.’s price is currently Undervalued.
Does Compass Therapeutics, Inc. pay dividends?
Compass Therapeutics, Inc. does not currently pay dividends.
What is Compass Therapeutics, Inc.’s EPS estimate?
Compass Therapeutics, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Compass Therapeutics, Inc. have?
Compass Therapeutics, Inc. has 180,087,920 shares outstanding.
What happened to Compass Therapeutics, Inc.’s price movement after its last earnings report?
Compass Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 5.291%.
Which hedge fund is a major shareholder of Compass Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.33 (350.89% Upside)
$9.33 (350.89% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.96%
Trailing 12-Months
Company Description
Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$9.33
▲(350.89% Upside)
Technical Analysis
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
12.74% Insiders
7.09% Mutual Funds
50.42% Other Institutional Investors
16.88% Public Companies and
Individual Investors